Personalized Risk Estimation for Crohn's Disease (PRE-Crohn's): Implementation and Feasibility
Launched by MASSACHUSETTS GENERAL HOSPITAL · Apr 11, 2022
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
The PRE-Crohn's trial is studying a new online tool designed to help people understand their risk of developing Crohn's disease, especially if they have a close family member (like a parent or sibling) with inflammatory bowel disease. This tool aims to provide personalized information about risk factors and may help encourage healthier behaviors and lifestyle changes that could lower the risk of developing the disease. The researchers believe that using this tool will be effective in changing behaviors and improving health markers compared to standard education about Crohn's disease.
To participate in this study, individuals must be over 14 years old and have at least one first-degree relative with inflammatory bowel disease. Participants will need to be willing to attend study visits and complete questionnaires about their health. It's important to note that this trial is not looking for individuals who already have inflammatory bowel disease or those who cannot provide informed consent. Overall, this research could lead to new ways to prevent Crohn's disease in those at higher risk.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Ability to give informed consent
- • Ability and willingness to comply with all patient visits and study-related procedures
- • Ability to understand and complete study questionnaires
- • Must have at least one first-degree relative with inflammatory bowel disease (Crohn's disease, ulcerative colitis, or indeterminate colitis/IBD unclassified)
- • Individuals greater than 14 years of age
- Exclusion Criteria:
- • Inability to provide informed consent
- • Inability to comply with all patient visits and study-related procedures
- • Inability to understand or complete study questionnaires
- • Patients with existing diagnoses of inflammatory bowel disease (ulcerative colitis, Crohn's disease, or indeterminate colitis/IBD unclassified)
- • Evidence of clinical signs or symptoms of inflammatory bowel disease, identified by a modified version of the Harvey-Bradshaw Index for CD activity
About Massachusetts General Hospital
Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Trial Officials
Emily Lopes, MD
Principal Investigator
Massachusetts General Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials